JP2024527940A - ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス - Google Patents

ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス Download PDF

Info

Publication number
JP2024527940A
JP2024527940A JP2024504834A JP2024504834A JP2024527940A JP 2024527940 A JP2024527940 A JP 2024527940A JP 2024504834 A JP2024504834 A JP 2024504834A JP 2024504834 A JP2024504834 A JP 2024504834A JP 2024527940 A JP2024527940 A JP 2024527940A
Authority
JP
Japan
Prior art keywords
alkyl
lipid
buffer
composition
nanoparticle composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527940A5 (https=
Inventor
エイチ スミス，マイケル
スード，ニミル
ティアン，チャン
ダブリュー ドハーティ，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2024527940A publication Critical patent/JP2024527940A/ja
Publication of JP2024527940A5 publication Critical patent/JP2024527940A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024504834A 2021-07-26 2022-07-25 ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス Pending JP2024527940A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225822P 2021-07-26 2021-07-26
US63/225,822 2021-07-26
PCT/US2022/038152 WO2023009422A1 (en) 2021-07-26 2022-07-25 Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium

Publications (2)

Publication Number Publication Date
JP2024527940A true JP2024527940A (ja) 2024-07-26
JP2024527940A5 JP2024527940A5 (https=) 2025-08-04

Family

ID=82899171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504834A Pending JP2024527940A (ja) 2021-07-26 2022-07-25 ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス

Country Status (6)

Country Link
US (1) US20240366522A1 (https=)
EP (1) EP4376815A1 (https=)
JP (1) JP2024527940A (https=)
CN (1) CN118019526A (https=)
TW (1) TW202320737A (https=)
WO (1) WO2023009422A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN118829423A (zh) * 2021-11-12 2024-10-22 摩登纳特斯有限公司 用于将有效载荷分子递送至气道上皮的组合物
CN121487722A (zh) * 2023-04-14 2026-02-06 北京剂泰生命科技有限公司 靶向脾的脂质纳米颗粒
WO2025111297A1 (en) 2023-11-21 2025-05-30 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
CN120718086A (zh) * 2024-06-13 2025-09-30 仁景(苏州)生物科技有限公司 用于递送的脂质化合物和脂质纳米颗粒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
AU2017357758B2 (en) * 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
US20210137840A1 (en) * 2018-04-25 2021-05-13 Ethris Gmbh Lipid-based formulations for the delivery of rna
JP7488193B2 (ja) * 2018-05-24 2024-05-21 トランスレイト バイオ， インコーポレイテッド チオエステルカチオン性脂質
CN118697900A (zh) * 2019-01-31 2024-09-27 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US20230181483A1 (en) * 2019-07-08 2023-06-15 Translate Bio, Inc. Improved mrna-loaded lipid nanoparticles and processes of making the same

Also Published As

Publication number Publication date
US20240366522A1 (en) 2024-11-07
CN118019526A (zh) 2024-05-10
WO2023009422A1 (en) 2023-02-02
TW202320737A (zh) 2023-06-01
EP4376815A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
JP2024527940A (ja) ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス
US20230285310A1 (en) Compositions for the delivery of payload molecules to airway epithelium
US20240335393A1 (en) Processes for preparing lipid nanoparticle compositions
US20250017867A1 (en) Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
US20250049727A1 (en) Compositions for the delivery of payload molecules to airway epithelium
AU2021377895A1 (en) Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20250214046A1 (en) Cross mixers for lipid nanoparticle production, and methods of operating the same
US20250313830A1 (en) Messenger ribonucleic acids with extended half-life
US20250049728A1 (en) Processes for preparing lipid nanoparticles
WO2024091918A2 (en) Methods of lipid nanoparticle production in cross-mixers
US20260014281A1 (en) Peg targeting compounds for delivery of therapeutics
WO2024197310A1 (en) Peg targeting compounds for delivery of therapeutics
US20240376445A1 (en) Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2024197309A1 (en) Peg targeting compounds for delivery of therapeutics
WO2024229321A1 (en) Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250725